PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICAPub 78
Pub 78
Balance Sheet
Fiscal Year Start:
Jan 1
Assets in 2024 (Year End)
$349,012,370
Investments
64%
Other Assets
15%
Cash & Equivalents
11%
Property, Plant, & Equipment (net)
9%
Prepaid Expenses
1%
Receivables (Non-Related)
<1%
Related-Party Receivables
0%
Inventories
0%
Liabilities in 2024 (Year End)
$190,475,115
Other Liabilities
51%
Payables & Accruals
33%
Deferred Revenue
16%
Grants Payable
0%
Tax-Exempt Bond Liabilities
0%
Custodial & Escrow Liabilities
0%
Notes Payable / Debt (Non-Related)
0%
Related-Party Payables
0%
Assets
2023
2024
Change
Cash & Equivalents
$221,437,642
$38,462,581
-83%
Receivables (Non-Related)
$1,364,512
$1,129,636
-17%
Related-Party Receivables
$0
$0
-
Inventories
$0
-
-
Prepaid Expenses
$3,896,851
$4,230,134
+9%
Investments
$91,073,945
$223,864,286
+146%
Property, Plant, & Equipment (net)
$25,409,340
$30,519,414
+20%
Other Assets
$55,768,387
$50,806,319
-9%
Total Assets
$398,950,677
$349,012,370
-13%
Liabilities
2023
2024
Change
Payables & Accruals
$56,663,492
$63,269,111
+12%
Grants Payable
$0
-
-
Deferred Revenue
$33,997,527
$29,904,508
-12%
Tax-Exempt Bond Liabilities
$0
-
-
Custodial & Escrow Liabilities
$0
-
-
Notes Payable / Debt (Non-Related)
$0
-
-
Related-Party Payables
$0
$0
-
Other Liabilities
$97,360,691
$97,301,496
0%
Total Liabilities
$188,021,710
$190,475,115
+1%
Net assets
2023
2024
Change
Restricted Net Assets
$0
-
-
Unrestricted Net Assets
$210,928,967
$158,537,255
-25%
Net assets
2023
2024
Change
Net assets
+$210,928,967
+$158,537,255
-25%
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)